Navigation Links
Cautious Optimism for New Alzheimer's Medications, Reports the Harvard Mental Health Letter
Date:10/9/2007

BOSTON, Oct. 9 /PRNewswire-USNewswire/ --- Alzheimer's disease takes a long time to develop, which suggests that it may be possible to design drugs that work early in the disease process, to delay the start of symptoms. Over the past decade, researchers have been testing a number of such "disease-modifying" drugs that target the earliest biological changes in Alzheimer's, reports the October 2007 issue of the Harvard Mental Health Letter.

None of the disease-modifying drugs now in development will cure Alzheimer's. But a number of them are currently in phase III clinical trials, the last stage before the FDA will consider approving the drugs for sale. Media interest has already begun to intensify. In June, for example, the AARP Bulletin trumpeted on its cover: "Finally, new drugs offer real hope for reversing the disease."

Two experts interviewed by the Mental Health Letter temper the optimism with caution.

The experts note that questions remain whether these drugs will be effective enough to block Alzheimer's or safe enough to be taken for a long time and with other medications.

A larger issue is whether the drugs aim at the right targets. The new disease-modifying drugs target early biological abnormalities, especially the sequence of events involved in the creation of amyloid plaques (a hallmark brain lesion in Alzheimer's). Dr. Michael Miller, editor in chief of the Harvard Mental Health Letter, notes that although most of the research effort so far has focused on this stage, researchers are still developing their understanding of how Alzheimer's develops. "Scientists are encouraged by their research into the details of the genetic and environmental causes of Alzheimer's," he says. "They look forward to identifying other interesting targets of treatment as the science evolves."

Also in this issue:

-- Depression and sleep apnea

-- The spiritual aspects of recovery

-- Alcohol abuse and dependence

-- Repeat autism screening

-- Chemistry of fear

-- What is Internet addiction?

The Harvard Mental Health Letter is available from Harvard Health Publications, the publishing division of Harvard Medical School, for $59 per year. Subscribe at http://www.health.harvard.edu/mental or by calling 1-877-649-9457 (toll free).

Media: Contact Christine Junge at Christine_Junge@hms.harvard.edu for a complimentary copy of the newsletter, or to receive our press releases directly.


'/>"/>
SOURCE Harvard Mental Health Letter
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Be cautious while on the Trampoline
2. Parents, More Cautious On Food Allergies
3. Precautious Measure Help Tolerate Nausea In Patients
4. Codeine-based painkillers to be used cautiously
5. Testing genes for disease does not cause harm to children of people with Alzheimers
6. Age-Dependent Alterations Not Specific For Alzheimers Disease
7. Killing two birds (cholesterol and Alzheimers disease) with the same stone
8. Exposure To High Aluminum Levels In Tap Water Lead To Rare Form Of Alzheimers
9. Sugar variant may make a world of difference to Alzheimers disease
10. Cancer Causing Protein May Heal Alzheimers
11. GAB2-A New Alzheimers Gene Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: